Clinical Trial Detail

NCT ID NCT02384954
Title ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Altor Bioscience Corporation
Indications

CLL/SLL

marginal zone B-cell lymphoma

lymphoplasmacytic lymphoma

follicular lymphoma

Therapies

ALT-803 + Rituximab

Age Groups: adult

No variant requirements are available.